cetrorelix

(redirected from Cetrotide)

cetrorelix

 [set″ro-rel´iks]
a gonadotropin-releasing hormone antagonist, used to inhibit premature luteinizing hormone surges in women undergoing controlled ovarian stimulation during infertility treatment; administered subcutaneously.

cetrorelix

/cet·ro·rel·ix/ (set″ro-rel´iks) a gonadotropin-releasing hormone antagonist, used as the acetate salt to inhibit premature surges of luteinizing hormone in women undergoing controlled ovarian stimulation during infertility treatment.

cetrorelix

[set′rorel′iks]
a gonadotropin-releasing hormone antagonist used to inhibit premature luteinizing hormone surges in women undergoing controlled ovarian stimulation during infertility treatment, administered subcutaneously.
References in periodicals archive ?
today announced the release of Cetrotide (generic name: Cetrorelix acetate), indicated for the prevention of premature ovulation.
Cetrotide was developed by Zentaris GmbH, a wholly-owned subsidiary of Canadian AEterna Zentaris Inc.
The lead LHRH antagonist compound, cetrorelix, is currently marketed for in vitro fertilization under the brand name Cetrotide.
The slow market growth is attributed to the patent expiry of the branded products such as Cetrotide and Ovidrel in 2015.
The slow market growth is attributed to the patent expiry of branded products such as Cetrotide and Ovidrel in 2015.
Tokyo, Japan, Sept 21, 2006 - (JCN) - Shionogi and Nippon Kayaku announced on September 21 the launch in Japan of Cetrotide - cetrorelix acetate, for prevention of premature ovulation during
Canadian biopharmaceutical company AEterna Zentaris, through German subsidiary Zentaris GmbH, is the worldwide licensor of development rights for Cetrotide, which is approved for prevention of premature ovulation in 93 countries, including countries in Europe and the United States.
Some key branded products such as Cetrotide, GONAL-f, Crinone, Ovidrel, Luveris, Pergoveris and Puregon are going to face severe threats from generics as they approach patent expiry between 2010 and 2015.
Tokyo, Japan, Apr 21, 2006 - (JCN) - Shionogi and Nippon Kayaku jointly announced on April 20 that they have received approval for Cetrotide, an agent for preventing premature ovulation, from the Ministry of Health, Labor and Welfare.
Cetrotide (cetrorelix acetate), which was developed by German company Zentaris AG, is currently available in 92 countries worldwide.
This team has invested in 34 pharmaceutical and medical device products through two HC Royalty investment funds including LYRICA,Oracea, Cetrotide, and PROCYSBI (TM), an orphan drug recently approved by the FDA for the treatment of nephropathic cystinosis.
The license agreement between AEterna Zentaris and Merck Serono was signed in 2000 and granted Merck Serono exclusive rights to market, distribute and sell Cetrotide worldwide, with the exception of Japan, in the field of in vitro fertilization.